iShares MSCI Malaysia ETF vs Moderna, Inc. — how do they compare? iShares MSCI Malaysia ETF trades at $28.01, while Moderna, Inc. trades at $63.75 (market cap $27.09B). Which is the better fit depends on your goals.
| EWM | MRNA | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $81.80 |
52-Week Low | $23.49 | $22.36 |
Market Cap | — | $27.09B |
Enterprise Value | — | $23.19B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.
Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.
Trailing returns across standard periods
Latest headlines on both assets
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →